Journal
BRAIN
Volume 141, Issue -, Pages 1263-1285Publisher
OXFORD UNIV PRESS
DOI: 10.1093/brain/awx327
Keywords
frontotemporal dementia; progressive supranuclear palsy; corticobasal degeneration; neurotransmitters; dementia
Categories
Funding
- Holt Fellowship
- Wellcome Trust [JBR 103838]
- National Institute for Health Research Cambridge Biomedical Research Centre
- Cambridge Brain Bank
- MRC [MC_UU_00005/12, MC_U105597119] Funding Source: UKRI
- Medical Research Council [MC_UU_00005/12, MC_U105597119] Funding Source: researchfish
- Wellcome Trust [103838/Z/14/Z] Funding Source: researchfish
Ask authors/readers for more resources
Frontotemporal lobar degeneration causes a spectrum of complex degenerative disorders including frontotemporal dementia, progressive supranuclear palsy and corticobasal syndrome, each of which is associated with changes in the principal neurotransmitter systems. We review the evidence for these neurochemical changes and propose that they contribute to symptomatology of frontotemporal lobar degeneration, over and above neuronal loss and atrophy. Despite the development of disease-modifying therapies, aiming to slow neuropathological progression, it remains important to advance symptomatic treatments to reduce the disease burden and improve patients' and carers' quality of life. We propose that targeting the selective deficiencies in neurotransmitter systems, including dopamine, noradrenaline, serotonin, acetylcholine, glutamate and gamma-aminobutyric acid is an important strategy towards this goal. We summarize the current evidence-base for pharmacological treatments and suggest strategies to improve the development of new, effective pharmacological treatments.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available